Literature DB >> 8123070

The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation.

S A Guidera1, J S Steinberg.   

Abstract

OBJECTIVES: This study was undertaken to determine the ability of the signal-averaged electrocardiogram (ECG) to identify evidence of delayed atrial activation in patients with a history of atrial fibrillation.
BACKGROUND: Atrial fibrillation is a reentrant rhythm and depends on atrial conduction delay for its development. The signal-averaging technique is useful for accurately measuring total cardiac activation times, including delayed low amplitude signals, and thus can help identify the substrate for reentrant arrhythmias.
METHODS: Standard 12-lead and signal-averaged ECGs were recorded from 15 patients with a documented history of prior paroxysmal or chronic atrial fibrillation and 15 age- and disease-matched control subjects without a history of atrial fibrillation. Signal averaging was performed using an orthogonal lead system with the QRS complex as a trigger and the P wave as a template for the signal-averaging process. Total P wave duration was measured before and after filtering with a least squares fit filter. The P wave complexes on the three bipolar leads were combined into a vector combination of orthogonal leads. The total P wave duration of the individual unfiltered and filtered leads and the vector combination of filtered leads were calculated and used for analysis.
RESULTS: The P wave duration by standard ECG was not significantly different in patients with a history of atrial fibrillation and control subjects. Signal-averaged P wave durations were measured from orthogonal leads before and after digital filtering. Mean unfiltered P wave duration was significantly longer in patients with a history of atrial fibrillation than in control subjects (132 +/- 22 vs. 114 +/- 14 ms [p < 0.03] in the X lead, 135 +/- 21 vs. 115 +/- 15 ms [p < 0.03] in the Y lead and 133 +/- 23 vs. 114 +/- 14 ms [p < 0.03] in the Z lead). Mean filtered P wave duration was also longer in patients with atrial fibrillation than in control subjects (151 +/- 23 vs. 130 +/- 19 ms [p < 0.01] in the X lead, 157 +/- 22 vs. 136 +/- 17 ms [p < 0.01] in the Y lead and 154 +/- 23 vs. 135 +/- 15 ms [p < 0.01] in the Z lead). After filtering, a vector composite of orthogonal leads was determined. Again, P wave duration in patients with a history of atrial fibrillation exceeded that in the control subjects (162 +/- 15 vs. 140 +/- 12 ms [p < 0.01]). Using the vector composite of filtered orthogonal leads, a P wave duration > or = 155 ms was associated with a sensitivity of 80%, a specificity of 93% and a positive predictive value of 92% for identifying patients with history of atrial fibrillation.
CONCLUSIONS: A prolonged signal-averaged P wave duration may be a simple noninvasive marker of the risk for development of atrial fibrillation.

Entities:  

Mesh:

Year:  1993        PMID: 8123070     DOI: 10.1016/0735-1097(93)90381-a

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

Review 1.  Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk.

Authors:  T E Cuddy
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery.

Authors:  A G Zaman; F Alamgir; T Richens; R Williams; M T Rothman; P G Mills
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 3.  Computational modeling of the human atrial anatomy and electrophysiology.

Authors:  Olaf Dössel; Martin W Krueger; Frank M Weber; Mathias Wilhelms; Gunnar Seemann
Journal:  Med Biol Eng Comput       Date:  2012-06-21       Impact factor: 2.602

4.  Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation.

Authors:  Gautam G Lalani; Amir Schricker; Michael Gibson; Armand Rostamian; David E Krummen; Sanjiv M Narayan
Journal:  J Am Coll Cardiol       Date:  2012-02-07       Impact factor: 24.094

5.  Signal-averaged P wave duration and the dimensions of the atria.

Authors:  Ulrik Dixen; Christian Joens; Bo V Rasmussen; Jan Parner; Gorm B Jensen
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

6.  Filtered signal-averaged P-wave duration during pneumoperitoneum in patients undergoing laparoscopic cholecystectomy: A reflection of pathophysiological cardiac changes.

Authors:  Amitai Bickel; Michael Marinovski; Alexander Shturman; Nathan Roguin; Igor Waksman; Arie Eitan
Journal:  Surg Endosc       Date:  2007-12-11       Impact factor: 4.584

7.  Electrocardiographic nature of restored sinus rhythm after Cox maze procedure in patients with chronic atrial fibrillation who also had other cardiac surgery.

Authors:  J Kamata; K Nakai; N Chiba; S Hosokawa; Y Sato; M Nasu; T Sasaki; H Kitahara; H Izumoto; Y Yagi; C Itoh; K Hiramori; K Kawazoe
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

8.  P-wave signal-averaged electrocardiogram predicts atrial fibrillation after coronary artery bypass grafting.

Authors:  Paolo Caravelli; Marco De Carlo; Giuseppe Musumeci; Giuseppe Tartarini; Gherardo Gherarducci; Uberto Bortolotti; Massimo A Mariani; Mario Mariani
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

9.  Maximum p wave duration and p wave dispersion in adult patients with secundum atrial septal defect: the impact of surgical repair.

Authors:  Umit Guray; Yesim Guray; Burcu Mecit; M Birhan Yilmaz; Hatice Sasmaz; Sule Korkmaz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

10.  Effects of right coronary artery PTCA on variables of P-wave signal averaged electrocardiogram.

Authors:  Marco Budeus; Marcus Hennersdorf; Stefan Dierkes; Michael Preik; Matthias P Heintzen; Malte Kelm; Christian Perings
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.